Short Wave A COVID-19 Vaccine: What You Need To Know
Jun 26, 2020
In this insightful discussion, Joe Palca, NPR science correspondent with extensive coverage of COVID-19 and vaccine development, shares his expertise. He reveals that around 200 vaccines are in active development, detailing the unique approaches to stimulate immune responses. Joe discusses the rapid manufacturing processes utilized during the pandemic and innovative solutions like microneedle patches. He also addresses the complex challenges of global distribution, raising questions about the future of annual vaccinations akin to the flu shot.
AI Snips
Chapters
Transcript
Episode notes
At-Risk Manufacturing
- Emergent BioSolutions is manufacturing a Covid vaccine from Novavax in Baltimore.
- They are doing at-risk manufacturing, meaning they produce it before approval.
The Gamble of At-Risk Manufacturing
- At-risk manufacturing of vaccines is a gamble due to potential ineffectiveness.
- However, it's necessary to expedite vaccine availability during a pandemic.
Vaccine Goal
- Over 100 Covid vaccines are in development, all aiming to trigger an immune response.
- They do this without causing illness, like showing a picture of a threat.